Add Press Release
About Us
Home
FAQ
Login
Oxy-Powder Clinical Studies Published in IJPBS
Users Blogs
Content Syndication
Architecture
Art and Entertainment
Automobile
Automotive
Business
Chemical
Computer
Computers
Consumer
Design
Economy
Education
Employment And Careers
Employment Opportunity
Environment
Events And Trade Shows
Events and Tradeshows
Gaming And Casinos
Government
Home And Family
Industry Specific
Industry Updates
IndustrySpecific
Insurance
Interviews
Legal And Law
Lifestyle
Machinery
Maritime
Medical
Miscellaneous
Non-profit
Opinion and Editorial
Others
Politics
Public Utilities
Religion
Science and Research
Society
Sports
Teaching and Learning
Technology
Telecom
Textile
Trade
Transportation
Volunteer
Oxy-Powder Clinical Studies Published in IJPBS
Clinical studies conducted on the colon cleansing product Oxy-Powder were published in the April issue of the International Journal of Pharma and Bio Sciences (IJPBS). The publication focused on four of many studies performed to test various aspects of Oxy-Powder’s effectiveness and safety. The studies addressed Oxy-Powder’s effects on constipation, Oxy-Powder’s impact on Irritable Bowel Syndrome (IBS), as well as animal toxicity and safety levels. The results indicated Oxy-Powder relieves constipation and the symptoms associated with IBS, and validated the nontoxic safety of the supplement.
Houston, TX, April 29, 2010 -- Clinical studies conducted on the all-natural
colon cleansing product
Oxy-Powder were published in the April issue of the International Journal of Pharma and Bio Sciences (IJPBS). These clinical trials are a milestone for the colon cleanse industry, as they prove the efficacy of Oxy-Powder in safely treating constipation and IBS.
The first study focused on Oxy-Powder’s effects on constipation. Among the study results are the following: 92.6% of the participants had straining during bowel movements on the first day. On the 42nd day, only 7.7% still had this symptom. Final results indicated that 57.7% of the patients treated with Oxy-Powder showed significant improvement.
The second study focused on Oxy-Powder’s impact on Irritable Bowel Syndrome (IBS). 100% of case study participants reported that with help from Oxy-Powder, symptoms of hard and lumpy stools were relieved within 21 days.
“These studies are scientific proof that Oxy-Powder is a safe and effective, all-natural way of treating constipation and IBS,” says Dr. Group, CEO of Global Healing Center, maker of Oxy-Powder. “We’re excited about these clinical studies encouraging more doctors to recommend Oxy-Powder for their patients who are interested in natural alternatives to unsafe laxatives.”
The third study published in International Journal of Pharma and Bio Sciences was an animal safety and toxicity study on Oxy-Powder. The case study results showed no signs of toxicity or clinical abnormalities associated with the use of the supplement.
These studies indicate Oxy-Powder safely relieves constipation and the symptoms associated with IBS.
About Oxy-Powder
Oxy-Powder® is a scientifically formulated, all natural oxygen colon cleanser used to safely relieve the bloating, irritation and constipation associated with a toxic colon. Backed with a 90-Day 100% money back guarantee, Oxy-Powder® provides the ultimate in
colon cleansing
to get you back on track to a healthier lifestyle. For more information, please visit http://www.oxypowder.com.
About Global Healing Center
Global Healing Center offers a wide variety of products and home health equipment such as air purifiers, water purifiers, hi-tech organic supplementation, radiation protectors, books and educational material and more. We are here to educate people in understanding what causes poor health and to help them achieve their health goals. We give people the tools they need to live a long, healthy, happy life. Please visit our site at
http://www.globalhealingcenter.com
.
Oxy-Powder Clinical Studies Published in IJPBS Summary
Clinical studies conducted on the colon cleansing product Oxy-Powder were published in the April issue of the International Journal of Pharma and Bio Sciences (IJPBS). The publication focused on four of many studies performed to test various aspects of Oxy-Powder’s effectiveness and safety. The studies addressed Oxy-Powder’s effects on constipation, Oxy-Powder’s impact on Irritable Bowel Syndrome (IBS), as well as animal toxicity and safety levels. The results indicated Oxy-Powder relieves constipation and the symptoms associated with IBS, and validated the nontoxic safety of the supplement.
Press Release Distribution By PressReleasePoint
Contact:
Dr.Edward F. Group
Oxy-Powder
Houston, TX
800-476-0016
editor@oxypowder.com
http://www.oxypowder.com
Terms
|
Privacy
|
Contact us
|
Site Map
|
Links
Sitemap
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
This website disclaims any content found in these news releases or articles. Issuers of news releases or articles are solely responsible for the accuracy of their content. If you have any questions regarding information in these news releases, please contact the issuers of the press releases.
© Copyright @ 2005. All rights Reserved. Use of our service is protected by our Privacy policy and Terms of Service.